Newlink Genetics Corp (NLNK) 25.76 $NLNK
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic
NewLink Genetics Corporation Reports First Quarter 2014 Financial Results
Marketwire - Wed May 07, 5:04AM CDT
NewLink Genetics Corporation (NASDAQ: NLNK) today reported consolidated financial results for the first quarter of 2014 and progress in its development programs.
Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
M2 - Wed Apr 16, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb45f5/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. The Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. The increase in technological advances and improved understanding of immunology and immunotherapy has enabled the discovery of many biomarkers, thus aiding the development of therapy through the body's natural defense mechanism. Vaccines are usually thought of as biologics, which elicit an immune response to initiate a defense mechanism. This led to the development of therapeutic vaccines, which can induce the immune system to attack the targeted diseased tissue with greater bioavailability and specificity with minimal side effects. Various strategies have been developed to make therapeutic vaccines viable alternatives to the existing therapeutic approaches. Thus, improved understanding of immunology and immunotherapy is expected to boost the growth of the Global Therapeutic Vaccines market. According to the report, the incidence of cancers, infectious diseases, and physiological disorders is widespread owing to poor lifestyle, low immunity, and unhygienic conditions. As a result, the incidence of disorders such as Alzheimer's disease, Parkinson's disease, cancer, diabetes, and infectious diseases such as Hepatitis B, HIV/AIDS, and HPV is rising. The manifestation of these ailments is expected to increase due to a rise in aging population. The use of these vaccines to treat such ailments will be boosted by an increase in prevalence of these diseases and disorders, thus boosting the growth of the market. Further, the report states that the stringent government regulations could lead to delays in production and additional manufacturing costs. Vendors transfer the burden of the extra costs onto the end-users, making the adoption of the vaccines challenging. Key Vendors - Agenus Inc. - Bavarian Nordic A/S. - Dendreon Corp. - GlaxoSmithKline plc - Novartis International AG Other Prominent Vendors - AFFiRiS AG. - Argos Therapeutics Inc. - Celldex Therapeutics Inc. - CEL-SCI Corp. - Cytos Biotechnology AG - GlobeImmune Inc. - NewLink Genetics Corp. - NovaRx Corp. - Oncothyreon Inc. - TVAX Biomedical Inc. - TapImmune Inc. - Vical Inc. - Vaccinogen Inc. Market Drivers/Trends/Challenges - Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders - Ongoing Development of a Large Number of Therapeutic Vaccines - Stringent Regulations - Adverse Side Effects of Therapeutic Vaccines - Increase in Mergers and Acquisitions Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Analysis - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zb45f5/global
NewLink Genetics Presents Data at the AACR 2014 Annual Meeting
Marketwire - Wed Apr 09, 10:15AM CDT
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, presented preclinical data related to the immunostimulatory and anti-tumor effects of its two clinical-stage checkpoint inhibitors targeting the IDO pathway, indoximod and NLG919, in combination with anti-PD-1/PD-L antibodies. The data was presented in a poster session at the American Association for Cancer Research (AACR) 2014 Annual Meeting. In addition, new compounds that mediate TDO (tryptophan-2,3-dioxygenase) activity were presented.
Pharma Opportunity/Analyzer Report: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017
M2 - Mon Apr 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/59k64h/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017" report to their offering. New Drug Launches Will Drive Rapid Growth in the US and EU Pancreatic Cancer Market from 2012-2017 The authors estimates that the value of the pancreatic cancer market in the US and 5EU (France, Germany, Italy, Spain, and the UK) in 2012 was $529m. This market is defined as sales of branded drugs and major generic regimens commonly prescribed for pancreatic cancer patients across the six major markets (6MM). Just over half of these sales, $275m (52%), were generated in the US, while sales in the 5EU were estimated at $254m (48%). By 2017, the end of the forecast period, The authors projects pancreatic cancer sales to rise to $1.63 billion in the US and 5EU, at a high Compound Annual Growth Rate (CAGR) of 25.2%. The authors expects the proportion of sales from the US to increase to 72%, with market share in the 5EU decreasing to 28% by 2017. The overall rapid increase in the market size across the 6MM is attributed to the launch of Celgene's Abraxane in 2013 in the US and 2014 in Europe, and the incorporation of five pipeline agents into US clinical practice by the end of the forecast period. The authors forecasts sales of Abraxane to rise significantly, from $21m in 2012 to $954m in 2017, at a CAGR of 115%; sales of Abraxane will represent nearly 60% of the pancreatic cancer market by the end of the forecast period. Major drivers of the pancreatic cancer market in the US and 5EU during the forecast period include the following: - The greatest driver of the pancreatic cancer market across the 6MM will be the strong and rapid adoption of premium-priced Abraxane in place of generic chemotherapy regimens, such as FOLFIRINOX (5-flourouracil [5-FU]/leucovorin/irinotecan/oxaliplatin) and gemcitabine monotherapy. The authors forecasts particularly strong growth in the US, the largest market for pancreatic cancer therapeutics, and the market where Abraxane is priced the highest. - Of the five new pipeline agents that will be launched during the forecast period, NewLink Genetics Corporation's algenpantucel-L is expected to garner the highest sales, and is expected to launch in both the resectable and unresectable locally-advanced settings. Other drugs with significant forecast sales by 2017 include Threshold Pharmaceuticals/Merck's TH-302, and Merrimack Pharmaceuticals' MM-398. - The incidence of pancreatic cancer is increasing across the 6MM, resulting in further treatment opportunities for premium-priced therapeutics. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Treatment Options 6 Unmet Needs Assessment and Opportunity Analysis 7 Research and Development Strategies 8 Pipeline Assessment 9 Pipeline Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/59...ityanalyze
3 Biggest Biotech Crashes in March
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 03, 5:30PM CDT
March was pretty rough for the biotech sector, but the drop in some biotech stocks was simply breathtaking . Celldex Therapeutics , Acceleron , and Newlink Genetics all tumbled more than 25% last month -- far more than the 10% drop in the ...
These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
at The Street - Tue Mar 25, 1:35PM CDT
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.
3 Biotechs Bucking the Downtrend
George Budwell, The Motley Fool - Motley Fool - Tue Mar 25, 10:30AM CDT
Mr. Market savaged the biotech sector yesterday. Specifically, 92% of small-caps were losers, 94% of mid-caps painted the tape red, and large caps saw a single winner, Gilead Sciences . Given the broad-based downtrend in the sector, I think it's...
NewLink Genetics to Present Data at the AACR 2014 Annual Meeting
Marketwire - Tue Mar 25, 6:15AM CDT
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, today announced that two poster presentations highlighting its IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor programs, will be presented at the upcoming American Association of Cancer Research (AACR) meeting which will take place April 5-9, 2014 in San Diego, CA.
Biotech Stock Mailbag: Amarin, Cytrx, Sangamo and 'Story Stocks'
at The Street - Fri Mar 21, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
NewLink Genetics (NLNK) Marked As A Dead Cat Bounce Stock
at The Street - Tue Mar 18, 1:22PM CDT
Trade-Ideas LLC identified NewLink Genetics (NLNK) as a "dead cat bounce" (down big yesterday but up big today) candidate
3 Biotech Stocks Spiking on Big Volume
at The Street - Thu Mar 13, 5:00AM CDT
Keep these biotech stocks trading on unusual volume on your radar.
Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 12, 9:50AM CDT
Last week's highlights include safety concerns regarding a new class of drugs and takeover rumors.
Financial Results, Clinical Study Updates, Clinical Trial Results, Business Spin-Offs, and New Joint Ventures - Analyst Notes on ARIAD, NewLink, Puma Biotechnology, Theravance, and Ohr Pharmaceutical
PR Newswire - Wed Mar 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), NewLink Genetics Corporation (NASDAQ: NLNK), Puma Biotechnology, Inc. (NYSE: PBYI), Theravance, Inc. (NASDAQ: THRX), and Ohr Pharmaceutical, Inc. (NASDAQ: OHRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
NewLink Genetics Corporation Reports Fourth Quarter and Year End 2013 Financial Results
eTeligis - Tue Mar 11, 3:01PM CDT
NewLink Genetics Corporation (NASDAQ: NLNK), today reported consolidated financial results for the fourth quarter and year end 2013 and reviewed key 2013 accomplishments.
NewLink Genetics' Shares Sink - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 12:36PM CDT
Share prices of NewLink Genetics fell 16.2% after the committee recommended continuation of its phase III pancreatic cancer study (IMPRESS) of HyperAcute Pancreas.
This Week in Biotech: Put It in Print
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 08, 1:05PM CST
With the SPDR S&P Biotech Index up 62% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Why Alpha Natural Resources, NewLink Genetics, and Furmanite Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Mar 07, 7:30PM CST
On Friday, investors wrestled with nervousness about the rapidly changing situation in Russia and Ukraine, but the stock market eventually closed with small gains that sent the S&P 500 to all-time highs. Yet, many stocks failed to feel the...
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic
NewLink Genetics Corporation Reports First Quarter 2014 Financial Results
Marketwire - Wed May 07, 5:04AM CDT
NewLink Genetics Corporation (NASDAQ: NLNK) today reported consolidated financial results for the first quarter of 2014 and progress in its development programs.
Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
M2 - Wed Apr 16, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb45f5/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. The Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. The increase in technological advances and improved understanding of immunology and immunotherapy has enabled the discovery of many biomarkers, thus aiding the development of therapy through the body's natural defense mechanism. Vaccines are usually thought of as biologics, which elicit an immune response to initiate a defense mechanism. This led to the development of therapeutic vaccines, which can induce the immune system to attack the targeted diseased tissue with greater bioavailability and specificity with minimal side effects. Various strategies have been developed to make therapeutic vaccines viable alternatives to the existing therapeutic approaches. Thus, improved understanding of immunology and immunotherapy is expected to boost the growth of the Global Therapeutic Vaccines market. According to the report, the incidence of cancers, infectious diseases, and physiological disorders is widespread owing to poor lifestyle, low immunity, and unhygienic conditions. As a result, the incidence of disorders such as Alzheimer's disease, Parkinson's disease, cancer, diabetes, and infectious diseases such as Hepatitis B, HIV/AIDS, and HPV is rising. The manifestation of these ailments is expected to increase due to a rise in aging population. The use of these vaccines to treat such ailments will be boosted by an increase in prevalence of these diseases and disorders, thus boosting the growth of the market. Further, the report states that the stringent government regulations could lead to delays in production and additional manufacturing costs. Vendors transfer the burden of the extra costs onto the end-users, making the adoption of the vaccines challenging. Key Vendors - Agenus Inc. - Bavarian Nordic A/S. - Dendreon Corp. - GlaxoSmithKline plc - Novartis International AG Other Prominent Vendors - AFFiRiS AG. - Argos Therapeutics Inc. - Celldex Therapeutics Inc. - CEL-SCI Corp. - Cytos Biotechnology AG - GlobeImmune Inc. - NewLink Genetics Corp. - NovaRx Corp. - Oncothyreon Inc. - TVAX Biomedical Inc. - TapImmune Inc. - Vical Inc. - Vaccinogen Inc. Market Drivers/Trends/Challenges - Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders - Ongoing Development of a Large Number of Therapeutic Vaccines - Stringent Regulations - Adverse Side Effects of Therapeutic Vaccines - Increase in Mergers and Acquisitions Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Analysis - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zb45f5/global
NewLink Genetics Presents Data at the AACR 2014 Annual Meeting
Marketwire - Wed Apr 09, 10:15AM CDT
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, presented preclinical data related to the immunostimulatory and anti-tumor effects of its two clinical-stage checkpoint inhibitors targeting the IDO pathway, indoximod and NLG919, in combination with anti-PD-1/PD-L antibodies. The data was presented in a poster session at the American Association for Cancer Research (AACR) 2014 Annual Meeting. In addition, new compounds that mediate TDO (tryptophan-2,3-dioxygenase) activity were presented.
Pharma Opportunity/Analyzer Report: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017
M2 - Mon Apr 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/59k64h/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017" report to their offering. New Drug Launches Will Drive Rapid Growth in the US and EU Pancreatic Cancer Market from 2012-2017 The authors estimates that the value of the pancreatic cancer market in the US and 5EU (France, Germany, Italy, Spain, and the UK) in 2012 was $529m. This market is defined as sales of branded drugs and major generic regimens commonly prescribed for pancreatic cancer patients across the six major markets (6MM). Just over half of these sales, $275m (52%), were generated in the US, while sales in the 5EU were estimated at $254m (48%). By 2017, the end of the forecast period, The authors projects pancreatic cancer sales to rise to $1.63 billion in the US and 5EU, at a high Compound Annual Growth Rate (CAGR) of 25.2%. The authors expects the proportion of sales from the US to increase to 72%, with market share in the 5EU decreasing to 28% by 2017. The overall rapid increase in the market size across the 6MM is attributed to the launch of Celgene's Abraxane in 2013 in the US and 2014 in Europe, and the incorporation of five pipeline agents into US clinical practice by the end of the forecast period. The authors forecasts sales of Abraxane to rise significantly, from $21m in 2012 to $954m in 2017, at a CAGR of 115%; sales of Abraxane will represent nearly 60% of the pancreatic cancer market by the end of the forecast period. Major drivers of the pancreatic cancer market in the US and 5EU during the forecast period include the following: - The greatest driver of the pancreatic cancer market across the 6MM will be the strong and rapid adoption of premium-priced Abraxane in place of generic chemotherapy regimens, such as FOLFIRINOX (5-flourouracil [5-FU]/leucovorin/irinotecan/oxaliplatin) and gemcitabine monotherapy. The authors forecasts particularly strong growth in the US, the largest market for pancreatic cancer therapeutics, and the market where Abraxane is priced the highest. - Of the five new pipeline agents that will be launched during the forecast period, NewLink Genetics Corporation's algenpantucel-L is expected to garner the highest sales, and is expected to launch in both the resectable and unresectable locally-advanced settings. Other drugs with significant forecast sales by 2017 include Threshold Pharmaceuticals/Merck's TH-302, and Merrimack Pharmaceuticals' MM-398. - The incidence of pancreatic cancer is increasing across the 6MM, resulting in further treatment opportunities for premium-priced therapeutics. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Treatment Options 6 Unmet Needs Assessment and Opportunity Analysis 7 Research and Development Strategies 8 Pipeline Assessment 9 Pipeline Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/59...ityanalyze
3 Biggest Biotech Crashes in March
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 03, 5:30PM CDT
March was pretty rough for the biotech sector, but the drop in some biotech stocks was simply breathtaking . Celldex Therapeutics , Acceleron , and Newlink Genetics all tumbled more than 25% last month -- far more than the 10% drop in the ...
These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
at The Street - Tue Mar 25, 1:35PM CDT
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.
3 Biotechs Bucking the Downtrend
George Budwell, The Motley Fool - Motley Fool - Tue Mar 25, 10:30AM CDT
Mr. Market savaged the biotech sector yesterday. Specifically, 92% of small-caps were losers, 94% of mid-caps painted the tape red, and large caps saw a single winner, Gilead Sciences . Given the broad-based downtrend in the sector, I think it's...
NewLink Genetics to Present Data at the AACR 2014 Annual Meeting
Marketwire - Tue Mar 25, 6:15AM CDT
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, today announced that two poster presentations highlighting its IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor programs, will be presented at the upcoming American Association of Cancer Research (AACR) meeting which will take place April 5-9, 2014 in San Diego, CA.
Biotech Stock Mailbag: Amarin, Cytrx, Sangamo and 'Story Stocks'
at The Street - Fri Mar 21, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
NewLink Genetics (NLNK) Marked As A Dead Cat Bounce Stock
at The Street - Tue Mar 18, 1:22PM CDT
Trade-Ideas LLC identified NewLink Genetics (NLNK) as a "dead cat bounce" (down big yesterday but up big today) candidate
3 Biotech Stocks Spiking on Big Volume
at The Street - Thu Mar 13, 5:00AM CDT
Keep these biotech stocks trading on unusual volume on your radar.
Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 12, 9:50AM CDT
Last week's highlights include safety concerns regarding a new class of drugs and takeover rumors.
Financial Results, Clinical Study Updates, Clinical Trial Results, Business Spin-Offs, and New Joint Ventures - Analyst Notes on ARIAD, NewLink, Puma Biotechnology, Theravance, and Ohr Pharmaceutical
PR Newswire - Wed Mar 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), NewLink Genetics Corporation (NASDAQ: NLNK), Puma Biotechnology, Inc. (NYSE: PBYI), Theravance, Inc. (NASDAQ: THRX), and Ohr Pharmaceutical, Inc. (NASDAQ: OHRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
NewLink Genetics Corporation Reports Fourth Quarter and Year End 2013 Financial Results
eTeligis - Tue Mar 11, 3:01PM CDT
NewLink Genetics Corporation (NASDAQ: NLNK), today reported consolidated financial results for the fourth quarter and year end 2013 and reviewed key 2013 accomplishments.
NewLink Genetics' Shares Sink - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 12:36PM CDT
Share prices of NewLink Genetics fell 16.2% after the committee recommended continuation of its phase III pancreatic cancer study (IMPRESS) of HyperAcute Pancreas.
This Week in Biotech: Put It in Print
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 08, 1:05PM CST
With the SPDR S&P Biotech Index up 62% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Why Alpha Natural Resources, NewLink Genetics, and Furmanite Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Mar 07, 7:30PM CST
On Friday, investors wrestled with nervousness about the rapidly changing situation in Russia and Ukraine, but the stock market eventually closed with small gains that sent the S&P 500 to all-time highs. Yet, many stocks failed to feel the...
